{"entity":{"id":"nct04774718","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","aka":[],"tldr":"A phase 1/2 trial of Alectinib in brain and spinal cord tumours, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors is a phase 1/2 interventional study registered as NCT04774718 by Hoffmann-La Roche, with 42 participants enrolled, started 2021-09-14 and due to reach its primary completion in 2032-02-28. Interventions recorded: Alectinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04774718","url":"https://clinicaltrials.gov/study/NCT04774718"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["alectinib"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04774718","phase":"1/2","setting":"A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available","sponsor":"Hoffmann-La Roche","enrolled":42,"outcomes":[]},"route":"/trials/nct04774718/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"}],"drug":[{"id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}